Related Experiment Video
Updated: May 10, 2026
07:03
In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
From NAFLD in clinical practice to answers from guidelines
Fabio Nascimbeni1, Raluca Pais, Stefano Bellentani
1University of Modena and Reggio Emilia, Modena, Italy.
Journal of Hepatology
|June 12, 2013
Summary
This review examines non-alcoholic fatty liver disease (NAFLD) awareness and clinical practice challenges. It synthesizes literature and guidelines to offer practical diagnostic and management suggestions for healthcare professionals.
Area of Science:
- Hepatology
- Internal Medicine
- Public Health
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a growing global health concern.
- Understanding awareness and knowledge gaps is crucial for effective disease management.
- Current clinical practices for NAFLD diagnosis and treatment require evaluation.
Purpose of the Study:
- To assess awareness and knowledge of NAFLD among the public and healthcare professionals.
- To analyze international and national guidelines for areas of consensus and divergence.
- To provide practical recommendations for NAFLD diagnosis and management in clinical settings.
Main Methods:
- Literature review of studies on NAFLD awareness across different populations.
- Critical assessment of position papers and clinical practice guidelines from hepatological societies.
- Synthesis of findings to identify clinical practice challenges and propose solutions.
Main Results:
- Varied levels of NAFLD awareness exist among the general population and medical specialists.
- Identified discrepancies in understanding current NAFLD recommendations and diagnostic difficulties.
- Highlighted areas of convergence and divergence in international and national guidelines.
Conclusions:
- Improved NAFLD awareness and education are needed for both the public and healthcare providers.
- Standardized approaches to NAFLD diagnosis and management are essential.
- Addressing identified challenges can enhance clinical practice and patient outcomes.
Keywords:
AASLDACGAFLDAGAAPWPAmerican Association for the Study of Liver DiseaseAmerican College of GastroenterologyAmerican Gastroenterological AssociationAsian-Pacific Working PartyCLDCLDACVDChinese Liver Disease AssociationClinical practiceEASLESPGHANEuropean Association for the Study of the LiverEuropean Society for Pediatric Gastroenterology, Hepatology and NutritionGPsGuidelinesHCCIASLIRItalian Association for the Study of the LiverLBLTsMRFsMSNAFLDNASHT2DUSalcoholic fatty liver diseasecardiovascular diseasechronic liver diseasegeneral practitionershepatocellular carcinomainsulin resistanceliver biopsyliver testsmetabolic risk factorsmetabolic syndromenon-alcoholic fatty liver diseasenon-alcoholic steatohepatitistype 2 diabetesultrasonographyRelated Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...